Dr Julia Kirshner, Founder and CEO zPREDICTA, discusses her team's aims to develop laboratory models that represent human disease for more accurate testing of anti-cancer therapeutics. zPREDICTA has created a system that allow the accurate reconstruction of human tissue so you can predict how drugs will work in a patient. zPREDICTA achieves this by using patient samples that are grown in a culture system and running combination treatments that patients will receive in the clinic. Join this webinar with Dr. Kirshner on automating tumor-specific 3D cultures for anti-cancer drug screening >>